MarketLens
Sign Up

Is Big Pharma's Patent Cliff Driving a New M&A Wave

7 months ago
SHARE THIS ON:

Is Big Pharma's Patent Cliff Driving a New M&A Wave

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•2 weeks ago

AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?

AbbVie's dividend survived Humira's patent cliff, defying the historical pattern in which a drugmaker's top product losing patent protection typically pressures the payout. The comparison raises the q...
Stock News•1 months ago

GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff

GSK's Specialty Medicines are driving growth, but an approaching HIV patent cliff is pushing the company to accelerate its pipeline.
Stock News•3 months ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Big Pharma is spending at a pace not seen since 2019 to replace ~$300B in drugs losing patent protection, fueling biotech acquisitions.

Breaking News

View All →

Top Headlines

View More →
Stock News•34 minutes ago

Apple's secret list of banned autocomplete phrases include ‘Dictator Trump,' ‘Sleepy Joe'

Stock News•51 minutes ago

Dave Ramsey Says You’ll "Never Touch" Your Retirement Principal If You Withdraw Less Than 12%. Here’s the Catch

Stock News•1 hour ago

GOOGL, GOOG FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Alphabet Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GOOGL, GOOG

Stock News•2 hours ago

Why Airbnb Stock Popped Today

Stock News•2 hours ago

Airbnb Surges 12% as Growth Accelerates and Outlook Rises | Closing Bell